Ocugen reported negative revenue for the fourth quarter driven by adjustments in collaborative arrangement revenue and posted a net loss as R&D spending increased to support clinical development programs. The company continued advancing multiple gene therapy candidates and ended the quarter with limited cash, supplemented by financing in early 2026 to extend its runway.

Ocugen's Q2 2025 results showed a slight year-over-year improvement in net loss as the company maintained momentum across multiple clinical trials. Key milestones included the start of pivotal trials for OCU410ST, continued dosing in OCU400, and progress on a Korean licensing agreement. Operating expenses declined slightly, and cash runway was extended into early 2026.

Ocugen reported a net loss of $15.4 million for Q1 2025, or $0.05 per share, compared to a net loss of $11.9 million, or $0.05 per share, in Q1 2024. Total revenue for the quarter was $1.5 million. The company ended the quarter with $38.1 million in cash and restricted cash.

Ocugen reported Q4 2024 revenue of $764,000, a decline from $1.4 million in Q4 2023. The company's net loss widened to $13.9 million due to higher research and development expenses. Cash and restricted cash increased to $58.8 million, extending the company's financial runway into Q1 2026.

Ocugen reported progress in its gene therapy programs, including the expansion of the OCU400 Phase 3 clinical trial into Canada. With recent financing, the company's cash runway extends into 1Q2026.

Ocugen reported second quarter 2024 financial results, highlighting progress in their modifier gene therapy platform, including dosing patients in the OCU400 Phase 3 clinical trial and advancing OCU410 into Phase 2. They also received $32.6 million net cash from a public offering, extending their cash runway into Q3 2025.

Ocugen reported a net loss of $11.924 million, or $0.05 per share, for the first quarter of 2024. The company's cash and cash equivalents totaled $26.4 million as of March 31, 2024. Ocugen is advancing its gene therapy programs, with OCU400 progressing to Phase 3 clinical trials.

Ocugen reported a net loss of $14.162 million, or $0.06 per share, for the third quarter of 2023. The company's cash, cash equivalents, and investments totaled $53.5 million as of September 30, 2023. Ocugen is advancing its pipeline, with OCU400 showing promising data and OCU500 being selected by NIAID for clinical trials.

I am sorry, but I am unable to provide a summary of the company's performance, key takeaways, or forward guidance, as the document provided does not contain any financial data.

Ocugen reported a net loss of $0.07 per share for the first quarter of 2023. The company's cash, cash equivalents, and investments totaled $76.7 million as of March 31, 2023, which is expected to fund operations into the first quarter of 2024.

Ocugen reported a net loss of $0.10 per share for the fourth quarter of 2022, compared to a net loss of $0.07 per share for the same period in 2021. Research and development expenses increased to $17.2 million from $7.1 million year-over-year, while general and administrative expenses decreased slightly to $6.9 million from $7.5 million.

Ocugen reported a net loss of $0.10 per share for the third quarter ended September 30, 2022. The company's cash, cash equivalents, and restricted cash totaled $101.6 million as of September 30, 2022. They believe that their current cash and cash equivalents balance will enable them to fund its operations into Q4 2023.

Ocugen reported its Q2 2022 financial results, highlighting progress in its vaccine and gene therapy programs, including the ongoing Phase 2/3 clinical trial for COVAXIN™ and the completion of Cohort 1 dosing in the OCU400 gene therapy clinical trial. The company also expanded its pipeline with the addition of NeoCart®, a Phase 3-ready cell therapy platform.

Ocugen reported a net loss of $0.09 per share for the first quarter of 2022. The company's cash, cash equivalents, and restricted cash totaled $129.9 million as of March 31, 2022. They also achieved a key milestone in its Phase 1/2 clinical trial for OCU400 of “first patient, first dose” in late March 2022 and expanded its rights to develop, manufacture, and commercialize COVAXIN™ to include Mexico.

Ocugen reported fourth quarter and full year 2021 financial results, highlighting the lifting of the clinical hold for COVAXIN™, progress in pediatric EUA submission, initiation of a Phase 1/2 clinical trial for OCU400, and a public offering of common stock.

Ocugen reported a net loss of $10.755 million, or $0.05 per share, for the third quarter of 2021. The company's cash, cash equivalents, and restricted cash totaled $107.5 million as of September 30, 2021. Ocugen filed an EUA for COVAXIN for children aged 2-18 years and two IND applications with the FDA.

Ocugen reported a net loss of $0.13 per share for the second quarter of 2021. The company's cash, cash equivalents, and restricted cash totaled $115.8 million as of June 30, 2021. Ocugen is focusing on regulatory submissions for COVAXIN™ and advancing its ophthalmic pipeline.

Ocugen reported a net loss of $7.077 million, or $0.04 per share, for the three months ended March 31, 2021. The company's cash, cash equivalents, and restricted cash totaled $44.9 million as of March 31, 2021. They are continuing to pursue EUA for COVAXIN while advancing their ophthalmology pipeline.

Ocugen reported full year 2020 financial results, highlighting progress towards offering a COVID-19 vaccine and curing blindness diseases, with ongoing efforts to develop an Emergency Use Authorization pathway for COVAXIN™ and plans to initiate clinical trials for OCU400.

Ocugen reported third quarter 2020 financial results with a net loss of $10.5 million, or $0.07 per share. The company's cash, cash equivalents, and restricted cash totaled $19.3 million as of September 30, 2020. Ocugen is on track to initiate four Phase 1/2a trials during 2021 and 2022.

Ocugen reported a net loss of $3.6 million, or $0.19 loss per share, for the three months ended June 30, 2020. The company's cash, cash equivalents and restricted cash totaled $15.1 million as of June 30, 2020. Ocugen sold an aggregate of 59.1 million shares of common stock in separate at-the-market offerings generating net proceeds of $15.4 million and increasing its cash runway into the first quarter of 2021.

Ocugen reported a net loss of $3.9 million, or $0.07 loss per share, for the three months ended March 31, 2020. The company's cash, cash equivalents and restricted cash totaled $3.3 million as of March 31, 2020. 100% of planned enrollment completed in Phase 3 oGVHD study; topline results anticipated by end of 2020

Ocugen reported a net loss of $20.2 million for the year ended December 31, 2019. The company's cash, cash equivalents and restricted cash totaled $7.6 million as of December 31, 2019. Over 95% planned enrollment completed in Phase 3 oGVHD study; topline results anticipated by end of 2020